McKesson Corporation $MCK Stock Sold by Ninety One UK Ltd

Key Points

• Ninety One UK Ltd reduced its McKesson stake by 13.9% in the third quarter, selling 6,270 shares and retaining 38,723 shares valued at approximately $33.1 million. Institutional investors collectively own 85.07% of the company.
• McKesson reported quarterly EPS of $9.93 and revenue of $105.38 billion, exceeding analyst expectations, while revenue increased 7.7% year over year. The company also raised its quarterly dividend to $0.94 per share.
• MCK shares have approached their 52-week high near $1,003, supported by bullish analyst actions; the stock carries a “Moderate Buy” consensus rating and an average price target of $983.29.

Ninety One UK Ltd lessened its stake in shares of McKesson Corporation (NYSE:MCK - Free Report) by 13.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 38,723 shares of the company's stock after selling 6,270 shares during the quarter. Ninety One UK Ltd's holdings in McKesson were worth $33,062,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of MCK. Nvwm LLC grew its position in shares of McKesson by 933.3% in the 3rd quarter. Nvwm LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 28 shares during the last quarter. Delos Wealth Advisors LLC acquired a new stake in McKesson during the 2nd quarter worth $27,000. Clearstead Trust LLC purchased a new stake in McKesson in the second quarter valued at $37,000. GK Wealth Management LLC purchased a new stake in McKesson in the third quarter valued at $38,000. Finally, Bell Investment Advisors Inc purchased a new stake in McKesson in the second quarter valued at $39,000. Institutional investors and hedge funds own 85.07% of the company's stock.

Insider Transactions at McKesson

In related news, Director Bradley E. Lerman sold 301 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $892.33, for a total transaction of $268,591.33. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the business's stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total value of $98,950.95. Following the completion of the transaction, the chief accounting officer owned 521 shares in the company, valued at $464,445.45. This trade represents a 17.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.06% of the stock is currently owned by corporate insiders.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Leerink raised its price target to $1,070, implying additional upside from recent levels and reinforcing the bullish analyst outlook. Leerink lifts target for McKesson stock to USD 1,070
• Positive Sentiment: Jim Cramer called McKesson a health-care “winner,” adding favorable high-profile commentary as the stock continues to outperform the broader market. Jim Cramer: This Health Care Stock Is A Winner
• Positive Sentiment: McKesson approached $1,000 after setting a fresh 52-week high near $998.64, signaling strong momentum and sustained demand for the shares. McKesson Approaches $1,000 After Setting a New 52-Week High
• Positive Sentiment: Separate coverage reported an all-time high around $1,000.97, while another report highlighted a $1.4 billion McKesson commitment, adding to the company’s favorable news flow. McKesson stock hits all-time high
• Neutral Sentiment: The rally follows McKesson’s latest quarterly results, which exceeded EPS and revenue expectations and showed 7.7% year-over-year revenue growth. However, the stock is near its 12-month high, which may increase sensitivity to profit-taking.

McKesson Price Performance

MCK stock opened at $997.40 on Friday. The company has a fifty day moving average price of $894.99 and a 200 day moving average price of $836.32. McKesson Corporation has a 12 month low of $723.68 and a 12 month high of $1,003.21. The company has a market cap of $116.29 billion, a price-to-earnings ratio of 26.69, a price-to-earnings-growth ratio of 1.94 and a beta of 0.30.

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, topping analysts' consensus estimates of $9.56 by $0.37. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The firm had revenue of $105.38 billion during the quarter, compared to analysts' expectations of $103.88 billion. During the same quarter in the prior year, the business earned $8.26 EPS. McKesson's quarterly revenue was up 7.7% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. As a group, analysts anticipate that McKesson Corporation will post 44.71 earnings per share for the current year.

McKesson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st were issued a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, September 1st. This is a positive change from McKesson's previous quarterly dividend of $0.82. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. McKesson's dividend payout ratio is currently 10.06%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on MCK. Bank of America raised their price objective on McKesson from $950.00 to $1,050.00 in a report on Thursday, August 6th. Barclays lifted their target price on McKesson from $925.00 to $1,000.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 19th. Wall Street Zen downgraded McKesson from a "buy" rating to a "hold" rating in a report on Saturday, June 27th. UBS Group upped their target price on McKesson from $1,050.00 to $1,080.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Finally, Evercore reissued an "outperform" rating and issued a $950.00 target price (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. Fifteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, McKesson has an average rating of "Moderate Buy" and an average target price of $983.29.

McKesson Company Profile

McKesson Corporation NYSE: MCK is a healthcare services and information technology company that distributes pharmaceuticals, specialty drugs, medical supplies and other healthcare products. The company serves pharmacies, hospitals, health systems, physician practices, biopharma manufacturers and other healthcare providers, helping move products from manufacturers to patients and care settings.

McKesson's principal operations include pharmaceutical distribution, medical-surgical supply distribution and technology-enabled services for pharmacies and providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.